公开(公告)号：US20240309115A1

公开(公告)日：2024-09-19

申请号：US18553114

申请日：2022-03-30

Applicant: MERUS N.V.

Inventor： Simon Edward PLYTE ,  Cornelis Adriaan DE KRUIF

IPC: C07K16/46 ,  A61K39/00 ,  A61P35/00 ,  C12N15/64

CPC classification number: C07K16/468 ,  A61P35/00 ,  C12N15/64 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565

Abstract: The present disclosure relates to a multispecific antibody comprising a binding domain that binds to LAG-3 and a binding domain that binds to PD-L1. Such multispecific antibody has comparable, or equal or higher, potency than a combination of LAG-3 and PD-L1 reference antibodies. Also provided is a method for treating a disease, in particular a disease associated with a suppressed immune system, such as cancer, with a multispecific antibody of the present disclosure. The present disclosure further relates to a vector and cell comprising nucleic acids encoding the heavy chain variable region of the LAG-3 and PD-L1 binding domains.

公开(公告)号：US20240309076A1

公开(公告)日：2024-09-19

申请号：US18259734

申请日：2021-12-29

Applicant: REGENXBIO INC. ,  NEURIMMUNE AG

Inventor： Danielle Sliter ,  Joseph Bruder ,  Devin McDougald ,  Fabio Montrasio ,  Jan Grimm ,  Chunping Qiao

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/28 ,  C12N15/86

CPC classification number: C07K16/18 ,  A61P25/28 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/522 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/02 ,  C12N2750/14143

Abstract: The present invention relates to nucleic acid expression cassettes that are engineered to express Tau-specific antibodies. Vectors and methods of employing the expression cassettes containing novel Tau-specific antibodies are provided. The invention is particularly useful for delivery of transgenes to target CNS cells and confers desirable properties for CNS-directed gene therapy. Moreover, the invention relates to a novel method of engineering, and expressing Tau-specific antibody transgenes for example within CNS cells, and delivery of therapeutics for treating various tauopathic diseases and disorders.

公开(公告)号：US12054537B2

公开(公告)日：2024-08-06

申请号：US16611943

申请日：2018-05-10

Applicant: The Wistar Institute of Anatomy and Biology ,  INOVIO PHARMACEUTICALS, INC.

Inventor： David Weiner ,  Ghiabe Guibinga ,  Neil Cooch ,  Charles Reed

IPC: C07K16/10 ,  C07K16/00 ,  A61K39/00 ,  A61K48/00 ,  C12N15/10 ,  G16B15/20 ,  G16B30/10

CPC classification number: C07K16/1027 ,  C07K16/00 ,  A61K2039/505 ,  A61K48/00 ,  C07K16/10 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/66 ,  C12N15/1031 ,  C12N15/1079 ,  G16B15/20 ,  G16B30/10

Abstract: Disclosed herein are compositions comprising structurally modified DNA encoded antibodies (DMAbs), methods of structurally modifying DMAbs, and methods of using structurally modified DMAbs.

公开(公告)号：US12054530B2

公开(公告)日：2024-08-06

申请号：US17150993

申请日：2021-01-15

Applicant: EpicentRx, Inc.

Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86

CPC classification number: C07K14/71 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/76 ,  C07K2319/01 ,  C07K2319/30 ,  C12N2710/10332 ,  C12N2710/10333 ,  C12N2710/10343 ,  C12N2710/10371

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20240254232A1

公开(公告)日：2024-08-01

申请号：US18575782

申请日：2022-06-21

Applicant: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD.

Inventor： Jie ZHAO ,  Haomin HUANG ,  Zhenping ZHU

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  C07K16/32

CPC classification number: C07K16/2818 ,  A61K47/6849 ,  C07K16/32 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/56

Abstract: A hexavalent trispecific antibody is a dimer formed by two monomers. Each monomer has a heavy chain, a first light chain, and a second light chain The first light chain and the second light chain are respectively combined with the heavy chain, so that the hexavalent trispecific antibody specifically binds to the first target, the second target, and the third target. The first target, the second target, and the third target can be PD-1, HER-2, and LAG-3.

公开(公告)号：US12049495B2

公开(公告)日：2024-07-30

申请号：US16871765

申请日：2020-05-11

Applicant: Novartis AG

Inventor： Huixiang Zhang ,  Charles Boring ,  Alok Kulshreshtha ,  Yuhong Zeng ,  Li Wan ,  Laman Alani

IPC: A61K39/395 ,  A61B3/12 ,  A61B5/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  C07K16/22 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61B3/12 ,  A61B5/4848 ,  A61K9/0048 ,  A61K39/3955 ,  A61K39/39591 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/94

Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

公开(公告)号：US20240158538A1

公开(公告)日：2024-05-16

申请号：US18518192

申请日：2023-11-22

Applicant: Hummingbird Bioscience Pte. Ltd.

Inventor： Jerome Boyd-Kirkup ,  Piers Ingram ,  Dipti Thakkar ,  Zhihao Wu ,  Konrad Paszkiewicz ,  Vicente Sancenon ,  Siyu Guan

IPC: C07K16/46

CPC classification number: C07K16/464 ,  C07K16/468 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/72

Abstract: VISTA antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the VISTA antigen-binding molecules.

公开(公告)号：US11976136B2

公开(公告)日：2024-05-07

申请号：US16932215

申请日：2020-07-17

Applicant: Eli Lilly and Company ,  The University of North Carolina at Chapel Hill

Inventor： Hector Aldaz ,  Shane Krummen Atwell ,  Stephen John Demarest ,  Karen Jean Froning ,  Brian Arthur Kuhlman ,  Andrew Philip Leaver-Fay

IPC: C07K16/46 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32

CPC classification number: C07K16/468 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.

公开(公告)号：US11976135B2

公开(公告)日：2024-05-07

申请号：US17063905

申请日：2020-10-06

Applicant: KYMAB LIMITED

Inventor： Wei Wang ,  E-Chiang Lee ,  John Kenneth Blackwood ,  Roberto Magliozzi

IPC: C07K16/36

CPC classification number: C07K16/36 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2317/94

Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.

公开(公告)号：US11958913B2

公开(公告)日：2024-04-16

申请号：US16476624

申请日：2018-01-09

Applicant: BIOMUNEX PHARMACEUTICALS

Inventor： Eugene Zhukovsky ,  Olivier Leger

IPC: C07K16/04 ,  A61K47/68 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46

CPC classification number: C07K16/468 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55

Abstract: The present invention relates to a mutant polypeptide linker for preparing multispecific antibodies, multispecific antibodies, and methods for producing multispecific antibodies.